Analysis of FDA-approved drug revenue cycles reveals asymmetry in therapeutic modalities and informs portfolio diversification strategies for new drugs in the era of price regulation.
Background
For a long time, new drug development companies have followed a linear product lifecycle model, aiming to defend against revenue decline starting from the patent expiration date. Recovering the substantial costs invested in R&D requires generating stable profits during the market exclusivity period. However, the IRA (Inflation Reduction Act) enacted by the U.S. government has brought about an unprecedented change, forcibly limiting the economic lifespan of new drugs from a regulatory perspective. According to the IRA, the timing for Medicare drug price negotiations differs between small-molecule chemical drugs, which are subject to negotiation 9 years after approval, and biologics, which are subject to negotiation 13 years after approval. This regulatory gap directly complicates the decision-making process for pharmaceutical companies in planning their pipeline R&D. Until now, there has been a lack of quantitative comparative analysis of how quickly and intensely new drugs generate revenue in the market, categorized by therapeutic modality or specific disease. This gap makes it difficult to accurately diagnose the actual impact of regulations on the market.
Key Findings
The researchers constructed a database of sales trends for 450 new drugs that received FDA approval between 2010 and 2025 and conducted empirical analysis. The analysis revealed that small-molecule chemical drugs and protein-based biologics showed distinct differences in their market entry speed and the timing of peak sales. Small-molecule drugs took an average of 6.2 years to reach peak sales after market entry, while biologics took an average of 8.5 years. Asymmetry in therapeutic modalities was also clearly observed in the rate of revenue decline after patent expiration. Small-molecule drugs showed a sharp vertical drop, with sales declining by up to 80% in the first year after patent expiration due to the influx of generic drugs. In contrast, biologics, which require complex manufacturing processes and stringent approval requirements, showed a more gradual decline, with an average annual sales decline of 15% over the 5 years following the launch of biosimilars. Variables related to therapeutic areas were also identified. Anticancer drugs and drugs for rare diseases achieved more than 60% of their total cumulative sales within the first 3 years after launch, demonstrating high initial concentration. In contrast, drugs for chronic diseases showed a characteristic of maintaining stable sales flows for more than 12 years. As a result, the 9-year period for small-molecule drug price negotiations proposed by the IRA effectively reduces the period for recovering investment in new small-molecule drugs to less than 3 years compared to the 13 years for biologics.
Significance and Outlook
The asymmetry in revenue cycles identified by the sales cycle analysis is expected to rapidly reshape the R&D investment landscape in the pharmaceutical industry. Major pharmaceutical companies are taking steps to intentionally reduce their pipelines of small-molecule chemical drugs, which carry higher regulatory risks. This trend raises concerns that it may stagnate R&D for relatively inexpensive, oral drugs, potentially limiting patient access to treatment in the long term. The concentration of portfolios on biologics or gene therapies is expected to lead to increased production costs and burden the healthcare insurance system. Therefore, policymakers should design a flexible pricing system that reflects the specific characteristics of therapeutic areas and the market entry speed of each modality, rather than applying a uniform 9-year and 13-year standard. Only when the pace of scientific and technological progress and the capital recovery cycle are in harmony can a sustainable innovation ecosystem be fully preserved.
Nature Biotechnology, Published online: 18 August 2026; doi:10.1038/s41587-026-03278-y An analysis of FDA-approved drugs reveals uneven timing and concentration of revenue life cycles across modalities and therapeutic areas, offering evidence to guide innovation strategy and policy design in a post-Inflation Reduction Act world.
Biotech and new drug development companies need to move away from the traditional development model that relies on gradual expansion of indications and adopt a compressed strategy to maximize sales early in the approval process. To preserve revenue before the drug price negotiation countdown begins, it is necessary to plan for targeting broad, high-value disease populations from the initial approval stage. Small-molecule drug developers can devise a speed-focused scenario in the early marketing phase by incorporating digital clinical data platforms to rapidly increase market share. This market penetration scenario can serve as a buffer to increase the capital recovery rate by more than 40% compared to the previous level within the limited 9-year non-negotiation period. Furthermore, even in joint development with multinational pharmaceutical companies, the presentation of precise indicators that demonstrate the value creation cycle before the regulatory implementation will become a key negotiating card, as much as the potential of the substance itself.